Analyst Ratings For CASI Pharmaceuticals (NASDAQ:CASI)
Today, HC Wainwright reiterated its Buy rating on CASI Pharmaceuticals (NASDAQ:CASI) with a price target of $4.50.
Some recent analyst ratings include
- 1/29/2018-HC Wainwright Reiterated Rating of Buy.
Recent Insider Trading Activity For CASI Pharmaceuticals (NASDAQ:CASI)
CASI Pharmaceuticals (NASDAQ:CASI) has insider ownership of 24.52% and institutional ownership of 3.67%.
- On 12/22/2017 Spectrum Pharmaceuticals Inc, Major Shareholder, bought 1,519,096 with an average share price of $0.01 per share and the total transaction amounting to $15,190.96.
- On 10/10/2017 Wei-Wu He, Director, bought 100,000 with an average share price of $1.95 per share and the total transaction amounting to $195,000.00.
- On 10/6/2017 Wei-Wu He, Director, bought 200,000 with an average share price of $1.83 per share and the total transaction amounting to $366,000.00.
- On 9/19/2017 Wei-Wu He, Director, bought 207,502 with an average share price of $1.75 per share and the total transaction amounting to $363,128.50.
- On 9/18/2017 Wei-Wu He, Director, bought 173,500 with an average share price of $1.75 per share and the total transaction amounting to $303,625.00.
- On 9/15/2017 Wei-Wu He, Director, bought 315,327 with an average share price of $1.33 per share and the total transaction amounting to $419,384.91.
- On 10/28/2016 Spectrum Pharmaceuticals Inc, Major Shareholder, bought 1,789,062 with an average share price of $0.01 per share and the total transaction amounting to $17,890.62.
Recent Trading Activity for CASI Pharmaceuticals (NASDAQ:CASI)
Shares of CASI Pharmaceuticals closed the previous trading session at 4.20 up +0.33 8.53% with 220685 shares trading hands.